advertisement
Abstract #28112 Published in IGR 13-1
Bimatoprost and bimatoprost/timolol fixed combination in patients with open-angle glaucoma and ocular hypertension
Katsanos A; Dastiridou AI; Fanariotis M; Kotoula M; Tsironi EEJournal of Ocular Pharmacology and Therapeutics 2011; 27: 67-71
Purpose: To investigate the intraocular pressure (IOP) lowering effect of bimatoprost (BIM) 0.03% and the potential additional effect of the BIM 0.03%/timolol 0.5% fixed combination (BTFC) in eyes with ocular hypertension, primary open-angle glaucoma, or exfoliation glaucoma. Methods: Following an appropriate washout period that varied with previous medication, participants with ocular hypertension, primary open-angle glaucoma, or exfoliation glaucoma were treated with evening-dosed BIM for 5 weeks. They were then given evening-dosed BTFC for another 5 weeks. One randomly selected eye was evaluated. Goldmann applanation tonometry was performed by the same investigator at 8 a.m., 12 noon, 4 p.m., and 8 p.m. at baseline and at the end of each treatment period. Results: Thirty-three participants completed the study. Three patients discontinued because of local adverse effects during the BIM treatment period. The mean diurnal IOP (mean(plus or minus)SD) at baseline, on BIM, and on BTFC were 24.8(plus or minus)5.4, 17.3(plus or minus)3.5, and 14.9(plus or minus)3.1 mmHg, respectively (repeated measures analysis of variance, P < 0.001 for all pairwise comparisons). The individual time-point IOP values showed similar significant reductions. The percentage of IOP reduction from baseline was 30.2% for BIM and 39.9% for the BTFC. The mean(plus or minus)SD diurnal fluctuation at baseline was 6.8(plus or minus)3.2 mmHg, which decreased to 4.0(plus or minus)3.1 and 2.9(plus or minus)1.4 mmHg on BIM and BTFC, respectively (P < 0.05 for both treatments versus baseline). Conclusions: Both BIM 0.03% and the BTFC were effective in lowering IOP in eyes with ocular hypertension and open-angle glaucoma. However, the fixed combination provided an additional statistically significant reduction in IOP compared with BIM 0.03%.
A. Katsanos. Department of Ophthalmology, University Hospital of Larissa, 66 Sina St., 41110 Mezourlo, Larissa, Greece. andreakatbp@hotmail.com
Classification:
11.13.2 Betablocker and carbon anhydrase inhibitor (Part of: 11 Medical treatment > 11.13 Combination therapy)
9.4.4.1 Exfoliation syndrome (Part of: 9 Clinical forms of glaucomas > 9.4 Glaucomas associated with other ocular and systemic disorders > 9.4.4 Glaucomas associated with disorders of the lens)
